Treatment of XXXX by a low molecular weight heparin fraction. A preliminary study.

@entity1 @entity2120 @entity548 @entity1151
We evaluated the antithrombotic efficacy of the low molecular weight heparin (LMWH) fraction @entity2120 in nine consecutive @entity1 with @entity1151 documented by pulmonary angioscan and angiography. Therapy with @entity2120 was initiated by an i.v. bolus of 0.5 mg/kg, followed by a continuous intravenous infusion during the first 10 days; the drug was then given subcutaneously twice daily during the following 15 days. The dosage of @entity2120 was adjusted by daily measurements of anti-Xa and anti-IIa activities using amidolytic methods. For a dosage ranging from 1.4 to 4.1 mg/kg per day during the i.v. period and from 0.7 to 3.5 mg/kg per day during the s.c. period, the anti-Xa activity ranged from 4 to 8.7 PK U/ml and from 4.5 to 7.2 PK U/ml respectively. Clinical improvement was observed in all the @entity1 and was consistent with progressive reperfusion evaluated by successive angioscans. No recurrence of @entity1151 occurred. No deleterious hemorrhagic side-effects were observed, even in two @entity1 at high risk of @entity548 . In this pilot study, the LMWH fraction @entity2120 proved to be an effective anticoagulant therapy during the first three weeks after @entity1151 in @entity1 .
